Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Blood (2017) 130 (15): 1772–1774.

https://doi.org/10.1182/blood-2017-07-795302

Published: 2017

Journal Articles

Effects Of Bendamustine Plus Rituximab On The Distribution Of Normal Peripheral Blood Leucocyte Populations In Advanced-Stage Chronic Lymphocytic Leukemia (CLL)

Georgiana Grigore, Martin Perez-Andres, PhD, Susana Barrena, Rosa Ana Rivas, Marcos González, MD, Pilar Rabasa, MD, Angeles Medina, Jose Francisco Tomas, MD, PhD, Fernando Solano, Javier De la Serna, MD, PhD, Jose García Marco, Mª José Allegue, Javier Loscertales, Inmaculada Pérez, Teresa Olave, MD, Julia Almeida, Alberto Orfao

Blood (2013) 122 (21): 5289.

https://doi.org/10.1182/blood.V122.21.5289.5289

Published: 2013

Journal Articles

Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM)

Laura Rosiñol, MD, Raquel Jiménez-Segura, Ana Isabel Teruel, MD, Javier De La Rubia, MD, PhD, Maria Victoria Mateos, MD, PhD, Miguel T. Hernandez, Dolores Hernández, M Jesús Blanchard, Belén Iñigo, Luis Palomera, MD, Isabel Krsnik, MD, PhD, Jose Francisco Tomas, MD, Norma C. Gutiérrez, Jesús F. San Miguel, MD, PhD, Juan José Lahuerta, Joan Blade, MD

Blood (2013) 122 (21): 3188.

https://doi.org/10.1182/blood.V122.21.3188.3188

Published: 2013

Journal Articles

Impact Of The Number Of Prior Treatment Lines Received On The Distribution Of Peripheral Blood Leukocyte Subsets In Advanced-Stage B-Cell Chronic Lymphocytic Leukemia (CLL)

Georgiana Grigore, Susana Barrena, Martin Perez-Andres, PhD, Miriam Fierro, Marcos González, MD, Pilar Rabasa, MD, Angeles Medina, José Francisco Tomás, Fernando Solano, Javier De la Serna, MD, PhD, Jose García Marco, Mª José Allegue, Javier Loscertales, Inmaculada PÉrez, Teresa Olave, MD, Julia Almeida, Alberto Orfao

Blood (2013) 122 (21): 4158.

https://doi.org/10.1182/blood.V122.21.4158.4158

Published: 2013

Journal Articles

A Phase 1/2 Study Of The Safety and Activity Of Escalating Doses Of Lenalidomide Plus Rituximab For Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia (LLC-Lenar-08)

Jose Francisco Tomas, MD, PhD, Marcos González, MD, Pilar Giraldo, MD PhD, Mª José Terol, Jose Antonio Pérez Simón, MD, PhD, Raquel de Oña, MD

Blood (2013) 122 (21): 5304.

https://doi.org/10.1182/blood.V122.21.5304.5304

Published: 2013

Journal Articles

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

Andres Forero-Torres, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Celeste M. Bello, MD, Thomas J. Kipps, MD, PhD, Fritz Offner, MD, Gregor Verhoef, Massimo Federico, MD, Stephanie A. Gregory, MD, Anne Sonet, MD, Sarit Assouline, MD, Jaime Pérez de Oteyza, Jose Francisco Tomas, MD, Antonio Cuneo, MD, Nairouz Elgeioushi, MPH, Trishna Goswami, MD, Ramy Ibrahim, MD, Ronald Herbst, PhD, Bruce D. Cheson, M.D.

Blood (2013) 122 (21): 1810.

https://doi.org/10.1182/blood.V122.21.1810.1810

Published: 2013

Journal Articles

A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90 y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization

Blood (2013) 122 (21): 369.

https://doi.org/10.1182/blood.V122.21.369.369

Published: 2013

Journal Articles

Bendamustine In Combination With Rituximab As First-Line Treatment For Indolent Non-Hodgkin Lymphoma: Retrospective Analysis Of An Spanish Registry

Silvia Solorzano, Carmen Martinez-Chamorro, Carlos Panizo, Cristina Quero, Guillermo Deben, MD, Jose Paz, Ana Batlle, MD, Alfons Serrano, Zayda Muentes, Antonio Gutierrez, MD, PhD, Jose Francisco Tomas, MD

Blood (2013) 122 (21): 5094.

https://doi.org/10.1182/blood.V122.21.5094.5094

Published: 2013

Journal Articles

Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial

Javier Briones, MD, Silvana Novelli, MD, Jose Antonio Garcia Marco, MD, Jose Francisco Tomas, MD, Teresa Bernal, MD, Carlos Grande, Miguel Canales, Antonio Torres, MD, José M. Moraleda, MD, Carlos Panizo, Fernanda Palmero, MD, Isidro Jarque, MD, Miguel Hernandez, MD, Eva Gonzalez Barca, MD, Dulce Lopez, Dolores Caballero, MD

Blood (2012) 120 (21): 1978.

https://doi.org/10.1182/blood.V120.21.1978.1978

Published: 2012

Journal Articles

MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

Blood (2012) 120 (21): 3677.

https://doi.org/10.1182/blood.V120.21.3677.3677

Published: 2012

Journal Articles

Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)

Antonio Salar, MD, Eva Domingo-Domenech, MD, Carlos Panizo, Concepción Nicolás, MD, Joan Bargay, Ana Muntanola, MD, Miguel Canales, Jose Luis Bello, MD, juan Manuel Sancho, Sr., MD, Jose Francisco Tomas, MD, María José Rodriguez, MD, Francisco-Javier Penalver, Luis Palomera, MD, Carlos Grande, José J Sánchez-Blanco, MD, Reyes Arranz, MD, Eulogio Conde, Dolores Caballero, MD, Carlos Montalban

Blood (2012) 120 (21): 3691.

https://doi.org/10.1182/blood.V120.21.3691.3691

Published: 2012

Journal Articles

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

Noridza Rivera-Rodriguez, MD, Fernando Cabanillas, MD, Carlos Montalban, Jose Francisco Tomas, MD, María José Terol, MD, PhD, Armando López-Guillermo, MD, Wandaly I. Pardo, MD, Orestes A. Pavia, MD, Margarita Bruno, MD, Karen Janice Santiago, Pablo Guisado-Vasco, MD, PhD, Angel Ruedas, MD, Raquel de Oña, Silvia Solorzano, Ana Isabel Teruel, MD, Laura Garcia-Sanchis, Jordina Rovira, MD, Ivan Dlouhy

Blood (2012) 120 (21): 1596.

https://doi.org/10.1182/blood.V120.21.1596.1596

Published: 2012

Journal Articles

5-Azacytidine Versus Intensive Chemotherapy or BSC in Elderly (>60 years) Acute Myeloid Leukemia Patients. A Retrospective Analysis

Josefina Serrano, Adolfo de la Fuente, MD, Juan Bergua, José Falantes, Martín-Chacón Eusebio, López Juan Antonio, Martinez-Losada MC, Casaño J, Antonio Romero, Prieto Elena, Mendez G, Tabares S, Jose Francisco Tomas, MD, PhD, Sánchez-Garcia Joaquin, Torres Antonio

Blood (2011) 118 (21): 2612.

https://doi.org/10.1182/blood.V118.21.2612.2612

Published: 2011

Journal Articles

Clofarabine in Acute Myeloid Leukemia. the Spanish Experience

Blood (2011) 118 (21): 4279.

https://doi.org/10.1182/blood.V118.21.4279.4279

Published: 2011

Journal Articles

Efficacy and Safety of Liposomal Cytarabine as Intrathecal Prophylaxis in Patients with Diffuse Large B Cell Lymphoma at High Risk of CNS Involvement: A Multicentric Study Including 80 Patients in Spain.

Adolfo de la Fuente, Sr., Antonio Salar, MD, PhD, Carlos Panizo, MD, Belen Navarro, Sr., Teresa Olave, María Jesus Peñarrubia, MD, JoaquÃn Herrero, MD, PhD, Jose Francisco Tomas, Miguel Canales, Eva González-Barca

Blood (2009) 114 (22): 1663.

https://doi.org/10.1182/blood.V114.22.1663.1663

Published: 2009

Journal Articles

NK Cytotoxicity Is Decreased During the Early Posttransplant Period Following Pediatric Allogeneic Transplantation From Unrelated Donors Using CD3/CD19-Depleted Graft.

Antonio Pérez-Martínez, MD, PhD, Manuel Ramírez, MD, PhD, María Ruiz-Salmerón, Marta Gonzalez-Vicent, MD, PhD, S. Grande, Alvaro Lassaletta, MD, Juliáan Sevilla, MD, PhD, Jose Francisco Tomas, MD, PhD, Luis Madero, MD, PhD, Prof, Miguel Angel Diaz, MD, PhD

Blood (2009) 114 (22): 2434.

https://doi.org/10.1182/blood.V114.22.2434.2434

Published: 2009

Journal Articles

Interim and End-of-Treatment 18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in Spain.

Eva Gonzalez-Barca, Miguel Canales, Antonio Salar, Albert Oriol, María Jesús Vidal, Joan Bargay, Montse Cortés, J. Coya, Jose Francisco Tomas, Andrés López, José Javier Sánchez, Eva Donato, Andrés Llorente, Secundino Ferrer, Dolores Caballero

Blood (2009) 114 (22): 3692.

https://doi.org/10.1182/blood.V114.22.3692.3692

Published: 2009

Journal Articles

Polymorphism -238 G/A in Promotor Region of Tumor Necrosis Factor alpha Gene Is a Risk Factor for Ischemic Cerebrovascular Disease in Spanish Population.

Jaime Fernandez De Velasco, MD, PhD, Pilar Llamas, MD, Raquel De Ona, MD, Ana Belen Santos, MD, Elena Meseguer, MD, Arancha Garcia-Raso, PhD, Raquel Mata, MD, Jose Francisco Tomas, MD

Blood (2004) 104 (11): 2604.

https://doi.org/10.1182/blood.V104.11.2604.2604

Published: 2004

Journal Articles

Factor V Leiden and Prothrombin G20210a Mutations in Young Adults with Ischemic Stroke.

Raquel De Ona, MD, Pilar Llamas, MD, Jaime Fernandez De Velasco, MD, PhD, Ana Belen Santos, MD, Elena Meseguer, MD, Arancha Garcia-Raso, PhD, Jose Francisco Tomas, MD

Blood (2004) 104 (11): 4058.

https://doi.org/10.1182/blood.V104.11.4058.4058

Published: 2004

Journal Articles

Polymorphisms of Methylenetetrahydrofolate Reductase Gene and Risk of Ischemic Stroke in a Spanish Population.

Raquel De Ona, MD, Pilar Llamas, MD, Jaime Fernandez De Velasco, MD PhD, Ana Belen Santos, MD, Elena Meseguer, MD, Arancha Garcia-Raso, PhD, Raquel Mata, MD, Jose Francisco Tomas, MD

Blood (2004) 104 (11): 3515.

https://doi.org/10.1182/blood.V104.11.3515.3515

Published: 2004

NARROW

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma

Effects Of Bendamustine Plus Rituximab On The Distribution Of Normal Peripheral Blood Leucocyte Populations In Advanced-Stage Chronic Lymphocytic Leukemia (CLL)

Characteristics and Outcome Of 66 Patients With Extramedullary Plasmacytomas (EMPs) Included In a Phase III Pethema/GEM Study Of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma (MM)

Impact Of The Number Of Prior Treatment Lines Received On The Distribution Of Peripheral Blood Leukocyte Subsets In Advanced-Stage B-Cell Chronic Lymphocytic Leukemia (CLL)

A Phase 1/2 Study Of The Safety and Activity Of Escalating Doses Of Lenalidomide Plus Rituximab For Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia (LLC-Lenar-08)

Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies

A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90 y Ibritumomab Tiuxetan (Zevalin®) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization

Bendamustine In Combination With Rituximab As First-Line Treatment For Indolent Non-Hodgkin Lymphoma: Retrospective Analysis Of An Spanish Registry

Autologous Stem Cell Transplantation with Yttriumm-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial

MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study

Final Results of a Multicenter Phase II Trial with Bendamustine and Rituximab As First Line Treatment for Patients with MALT Lymphoma (MALT-2008–01)

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

5-Azacytidine Versus Intensive Chemotherapy or BSC in Elderly (>60 years) Acute Myeloid Leukemia Patients. A Retrospective Analysis

Clofarabine in Acute Myeloid Leukemia. the Spanish Experience

Efficacy and Safety of Liposomal Cytarabine as Intrathecal Prophylaxis in Patients with Diffuse Large B Cell Lymphoma at High Risk of CNS Involvement: A Multicentric Study Including 80 Patients in Spain.

NK Cytotoxicity Is Decreased During the Early Posttransplant Period Following Pediatric Allogeneic Transplantation From Unrelated Donors Using CD3/CD19-Depleted Graft.

Interim and End-of-Treatment 18F-FDG-PET Evaluation of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment: An Open-Label Clinical Trial in Spain.

Polymorphism -238 G/A in Promotor Region of Tumor Necrosis Factor alpha Gene Is a Risk Factor for Ischemic Cerebrovascular Disease in Spanish Population.

Factor V Leiden and Prothrombin G20210a Mutations in Young Adults with Ischemic Stroke.

Polymorphisms of Methylenetetrahydrofolate Reductase Gene and Risk of Ischemic Stroke in a Spanish Population.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only